{
    "2018-02-09": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Solid Q4 Earnings Drive Pharma ETF Outlook",
                "features": {
                    "keywords": [
                        "Q4 Earnings",
                        "Pharma",
                        "ETF",
                        "Outlook"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "A Look at Amgen’s Nplate, Vectibix, and Neupogen in 4Q17",
                "features": {
                    "keywords": [
                        "Amgen",
                        "Nplate",
                        "Vectibix",
                        "Neupogen",
                        "4Q17"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "See what the IHS Markit Score report has to say about Eli Lilly And Co.",
                "features": {
                    "keywords": [
                        "IHS Markit Score",
                        "Eli Lilly",
                        "report"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "How Amgen’s Xgeva and Prolia Performed in 4Q17",
                "features": {
                    "keywords": [
                        "Amgen",
                        "Xgeva",
                        "Prolia",
                        "4Q17"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}